POLISCOPE
Back to bills
Part ofHealth →

The civic record

Read. Follow. Verify.

New Jersey Expands Newborn Screening Advisory Committee Responsibilities and Mandates Disorder Reviews

Original title: Expands responsibilities of Newborn Screening Advisory Review Committee.

Last action · October 19, 2026: Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens CommitteeSponsor: Joseph F. Vitale

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

This bill expands the responsibilities and membership of the Newborn Screening Advisory Review Committee and establishes strict timelines for reviewing federal and state screening panels. Beginning January 1, 2027, the committee must review new federal additions within one year, provided screening assays and FDA-approved treatments exist.

Why it matters

The measure establishes mandatory deadlines for evaluating eight specific rare conditions—including various types of and Batten disease—for inclusion in the state's mandatory newborn screening panel, affecting future screening requirements for newborns and testing protocols for medical providers.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Newborns

Newborns may become subject to mandatory screenings for additional genetic and heritable disorders if recommendations are approved.

Directly affected

Medical, hospital, and public health professionals

Professionals are represented on the review committee and will be required to implement new screening protocols established by the commissioner.

Directly affected

Commissioner of Health

The commissioner is required to review formal committee recommendations, approve or reject them, and adopt rules and regulations to implement the act.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What triggers the committee to review a new disorder?
A review is triggered if a is available and there is a therapeutic intervention or treatment approved by the U.S. Food and Drug Administration.
What specific conditions must be reviewed starting in late 2027?
The committee must review Sanfilippo syndrome type A, Morquio syndrome type A, Maroteaux Lamy syndrome, Sly syndrome, Batten disease type 2 (CLN2), Fabry disease, Gaucher disease, and Acid sphingomyelinase deficiency.
How much advance notice is required before a new screening is mandated?
The department must implement policies and procedures to ensure newborns are screened at least 60 days prior to the requirement taking effect, assuming the commissioner approves the recommendation.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

1 action
  1. Oct 19, 2026SenateIntroduced
    Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift95% confidence

Mandatory Review Timelines for Rare Disorders

The bill transitions the Newborn Screening Advisory Review Committee from discretionary annual reviews to strict statutory deadlines tied to federal panel updates and specific rare disease criteria.

Connected Entities

Newborn Screening Advisory Review Committee, United States Food and Drug Administration, Commissioner of Health and 2 more
OrganizationNewborn Screening Advisory Review Committee“Committee responsible for reviewing and advising the Commissioner of Health on d”Map →
OrganizationUnited States Food and Drug Administration“Federal agency approving therapeutic interventions and treatments for disorders.”Map →
PersonCommissioner of Health“State official responsible for approving committee recommendations and adopting ”Map →
PersonJoseph F. Vitale“Primary sponsor of Senate Bill No. 4857 representing District 19.”Map →

Sources

Open source document

njleg.state.nj.us

Analysis Score

0–100
  • Significance45
    How much this matters to a regular citizen
  • Controversy10
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz15
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record